Why does first-line therapy carry so much weight in HER2-positive metastatic breast cancer? With up to 30% of patients never reaching second-line treatment, choosing the most effective option upfront can define long-term outcomes. This clip revisits the historical THP standard and sets the stage for why newer strategies are being reconsidered.
Why First-Line Therapy Matters in HER2+ Metastatic Breast Cancer
You may also like
Recommended Videos
